Baird raised the firm’s price target on Cardinal Health to $128 from $126 and keeps an Outperform rating on the shares. The firm said the company remains their 2024 best idea given increased confidence in leadership, strong pharma distribution sector fundamentals, operational improvement execution, strong balance sheet and cash flow, attractive valuation and further return potential from dividends and share repos.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CAH:
- Cardinal Health raises FY24 EPS view to $6.75-$7.00 from $6.50-$6.75
- Early notable gainers among liquid option names on January 3rd
- Barclays starts healthcare technology, distribution with Neutral view
- Cardinal Health initiated with an Overweight at Barclays
- Buy/Sell: Wall Street’s top 10 stock calls this week
